EICHOR
● Completed
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
Condition: Atopic Dermatitis · Moderate-to-severe Atopic Dermatitis · Sponsor: Amgen
About this study
The primary objectives of this study are to: * estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus response at Week 24 * estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-meningococcal response at Week 24
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (85)
| Affiliated Dermatology | Scottsdale, Arizona, United States | — |
| Center for Dermatology and Plastic Surgery | Scottsdale, Arizona, United States | — |
| Scottsdale Clinical Trials | Scottsdale, Arizona, United States | — |
| Medical Advancement Centers of Arizona | Tempe, Arizona, United States | — |
| Little Rock Allergy and Asthma Clinical Research Center | Little Rock, Arkansas, United States | — |
| Kern Research Inc | Bakersfield, California, United States | — |
| Hope Clinical Research LLC | Canoga Park, California, United States | — |
| Doc1 Healthcare Systems | Chino, California, United States | — |
| 310 Clinical Research | Inglewood, California, United States | — |
| Chemidox Clinical Trials Incorporated | Lancaster, California, United States | — |
| Long Beach Research Institute | Long Beach, California, United States | — |
| University of California Los Angeles | Los Angeles, California, United States | — |
+ 73 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05899816